Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.14 per share, up 20.18% from the opening bell on heavy buying pressure. As of 11/18/09, the biopharmaceutical company announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.

CytRx President and CEO Steven A. Kriegsman said, “This planned clinical trial is a key step forward in our plans to build a commercial oncology franchise for CytRx. We have studied the oncology market in solid tumors and believe that stomach cancer represents a major market and an unmet medical problem worldwide. We have also been encouraged by exciting animal data for INNO-206 in a broad array of cancer indications, and

...

In the great state of Tennessee, there is a company that is on the cutting edge of cancer research and has taken their technology worldwide in an attempt to help cure the disease. The company is Provectus Pharmaceuticals and if they achieve continued success, they may soon be a well known name.

Provectus Pharmaceuticals is a development-stage oncology and dermatology biopharmaceutical company which uses the agent PV-10 as a therapeutic agent for a broad spectrum of cancers. Currently, PV-10 is available for select cancer patients in the U.S. but the program was initiated in Australia in June of 2009 and has excelled across the globe.

In the U.S., the PV-10 program commenced at St. Luke’s Hospital and Health Network in Bethlehem, PA under the watchful eye of the renowned Dr. Sanjiv Agarwaia who served as the Principal Investigator at that site for the Phase 2 Melanoma Trial. The U.S.

...

Lifeline Biotechnologies Inc.

(Public, PINK:LLBO)

With the recent gains in Hard to Treat Diseases Inc. (PINK:HTDS) and BioElectronics Corp. (OTC:BIEL), investors were left hungry for more undervalued, high potential biotech companies — Then came LifeLine Biotechnologies Inc (OTC:LLBO). As technology continues to redefine the modern era of medical advancements, certain companies will stand apart from the rest, as is the case with Lifeline Biotechnologies Inc. This company is an innovative medical technology company committed to the improvement of the quality of life through exceptional health care systems, focusing on prevention, early diagnosis, and quick recovery. Recently, the company has made headlines with their innovative Breast Cancer detection system, the First Warning System ™, a dynamic test which collects information over time with an uncanny efficacy. The next several months will prove to be critical for LifeLine Biotechnologies, as they await the FDA’s decision

...

In a major development today, the US Food and Drug Administration (FDA) approved Roche’s (RHHBY) Valcyte (valgancyclovir) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients. The drug targets patients aged 4 months to 16 years, who are at higher risk of developing the infection due to reduced immunity following organ transplants. The FDA also approved a pediatric oral solution of the drug.

Although the virus lies dormant in the body throughout life, it has the potential to cause severe damage when the immunity system is weakened. For transplant patients, the virus can lead to loss of the transplanted organ and in severe cases may even be fatal.

The recent approval represents a label expansion for the drug, which is already approved for CMV disease in HIV patients. In July 2008, it received pediatric exclusivity from the FDA. Combined sales of Valcyte and

...